Viewbix (VBIX) 10-K 17 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Apr. 17, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Virtual Crypto Technologies, Inc.
Entity Central Index Key	797,542
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 26,920
Entity Common Stock, Shares Outstanding		59,206,415
Trading Symbol	MRLA
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2017		Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,959		$ 4,486
Other receivables (Note 2)	12,222		9,356
Total current assets	15,181		13,842
Restricted cash	59		11,925
Fixed assets, net of accumulated depreciation of $26,120 at December 31, 2017 and $8,607 at December 31, 2016	14,290		31,803
Total assets	29,530		57,570
Current liabilities:
Accounts payable and accrued liabilities (Note 3)	445,653		198,795
Accounts payable - related party (Note 7)	82,331		125,962
Employee payable	98,476		161,341
Accrued interest payable (Note 5)	71,162		32,768
Short term portion of convertible notes (Note 5)	317,635		439,331
Derivative Liability (Note 5)			336,272	[1]
Total current liabilities	1,011,941		1,294,469
Convertible notes (Note 5)	606,165
Total liabilities	1,618,106		1,294,469
Stockholders’ deficit
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 529 and none issued at December 31, 2017 and December 31, 2016, respectively.		[2]
Common stock, $0.0001 par value; 490,000,000 shares authorized; 22,543,008 and 19,962,728 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively. (Note 6)	2,255		1,994
Accumulated other comprehensive income	(19,337)		(19,337)
Additional paid-in capital (Note 6)	14,968,925		13,826,957
Receipt on account of shares (Note 6)	80,000
Accumulated deficit	(16,620,419)		(15,046,513)	[1]
Total stockholders’ deficit	(1,588,576)		(1,236,899)
Total liabilities and stockholders’ deficit	$ 29,530		$ 57,570
[1]	Restated - see Note 10.
[2]	less than $1

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Fixed assets, accumulated depreciation	$ 26,120	$ 8,607
Preferred stock description	less than $1
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	529
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares issued	22,543,008	19,962,728
Common stock, shares outstanding	22,543,008	19,962,728

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues
Expenses:
Research and development	(354,809)	(1,644,868)
General and administrative expenses	(911,581)	(3,749,867)
Total operating expenses	(1,266,390)	(5,394,735)
Loss from operations	(1,266,390)	(5,394,735)
Finance income (expense):
Finance expense	(307,516)	(750,462)	[1]
Net loss attributable to shareholders of the company	(1,573,906)	(6,145,197)	[1]
Net loss attributable to shareholders of preferred stock	(39,491)
Net loss used in the calculation of basic and diluted loss per share	$ (1,534,415)	$ (6,145,197)	[1]
Basic and diluted net loss per share	$ (0.07)	$ (0.32)	[1]
Weighted average shares outstanding - basic and diluted	21,780,899	18,966,032
[1]	Restated - see Note 10.

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating Activities:
Net loss	$ (1,573,906)	$ (6,145,197)	[1]
Depreciation expense	17,513	12,422
Interest and amortization of discount on convertible notes	350,208	369,588
Shares issued for services		2,263,304
Change in derivative liability	(336,272)	309,873
Share based compensation	76,616	2,028,803
Non cash finance, general and administrative expenses arising from settlement with debt and warrant holders	659,960
Increase in accounts payable and accrued liabilities	183,993	123,869
Decrease in amounts due from related party	(40,339)	122,482
Decrease in accrued interest	35,078	13,483
Increase in other receivables	(2,866)	16,441
Net cash used in operating activities	630,015	(858,533)
Investing Activities:
Decrease (increase) in restricted cash	11,866	(11,925)
Purchase of fixed assets		(23,105)
Net cash provided by investing activities	11,866	(35,030)
Financing Activities:
Issuance of common stock (net of issuance expenses)	536,613	47,600
Issuance of short-term convertible notes		735,000
Receipt on account of stock	80,000
Net cash provided by financing activities	616,613	782,600
Effect of exchange rates on cash and cash equivalents
Net increase (decrease) in cash	(1,527)	(110,963)
Cash and cash equivalents - beginning of period	4,486	115,449
Cash and cash equivalents - end of period	2,959	4,486
Non-cash transactions:
Issuance of Preference Shares in connection with settlement with debt and warrant holders	529,000
Extinguishment of convertible note	(470,200)
Re issuance of convertible note	$ 606,160
[1]	Restated - see Note 10.

Statement of Changes in Stockho

Statement of Changes in Stockholders' Deficit - 12 months ended Dec. 31, 2017 - USD ($)	Common Stock [Member]	Preferred Stock [Member]		Additional Paid-in Capital [Member]	Receipt on Account of Shares [Member]	Other Comprehensive Income [Member]	Accumulated Deficit [Member]		Total
Balance at Dec. 31, 2016	$ 1,994			$ 13,826,957		$ (19,337)	$ (15,046,513)	[1]	$ (1,236,899)
Balance, shares at Dec. 31, 2016	19,931,478
Common stock issued for cash	$ 132			526,081					526,213
Common stock issued for cash, shares	1,315,563
Cashless exercise of Warrants	$ 110			(110)
Cashless exercise of Warrants, shares	1,096,395
Conversion of Convertible Note to shares	$ 7			10,393					10,400
Conversion of Convertible Note to shares, shares	74,572
Issuance of Ordinary Shares, value	$ 12			(12)
Issuance of Ordinary Shares	125,000
Issuance of Preferred Stock value			[2]	529,000					529,000
Issuance of Preferred Stock, shares		529
Receipt on Account of Shares					80,000				80,000
Share based compensation				76,616					76,616
Net loss for the year							(1,573,906)		(1,573,906)
Balance at Dec. 31, 2017	$ 2,255			$ 14,968,925	$ 80,000	$ (19,337)	$ (16,620,419)		$ (1,588,576)
Balance, shares at Dec. 31, 2017	22,543,008	529
[1]	Restated - see Note 10.
[2]	less than $1

Statement of Changes in Stockh7

Statement of Changes in Stockholders' Deficit (Parenthetical)	12 Months Ended
	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Preferred stock description	less than $1

The Company and Significant Acc

The Company and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
The Company and Significant Accounting Policies	Note 1. The Company and Significant Accounting Policies. Organizational Background: Emerald Medical Applications Corp (the “Company” or “Registrant”), was incorporated in the State of Ohio in 1989 under a predecessor name, Zaxis International Inc. (“Zaxis”). On August 25, 1995, Zaxis merged with a subsidiary of The InFerGene Company, a Delaware corporation, which entity changed its name to Zaxis International Inc. and the Company was reincorporated in Delaware as Zaxis. On December 30, 2014, Zaxis entered into a Memorandum of Understanding with Emerald Medical Applications Ltd., which was then a private limited liability company incorporated under the laws of the State of Israel (“Emerald Israel” or “Emerald”). On March 16, 2015, Zaxis and Emerald Israel executed the Share Exchange Agreement, which closed on July 14, 2015. The Share Exchange Agreement was accounted for as a reverse recapitalization. As a result, the historical financial statements of the Registrant were replaced with the historical financial statements of Emerald Israel. The Company and its subsidiary, Emerald, are collectively referred to as the “Company”. Emerald, a wholly-owned subsidiary of the Registrant effective July 14, 2015, was organized as a privately-owned company under the laws of the State of Israel on February 17, 2010. Emerald is a mobile digital-health startup company engaged in the development, sale and service of imaging solutions utilizing its proprietary DermaCompare software that it developed for use in derma imaging and analytics (“DermaCompare”). Emerald believes that its proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients’ skin characteristics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography (“TBP”), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smart phones or tablets. These TBP images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software. Beginning in July 2017, the Company commenced a process of outsourcing the development and maintenance of our patented DermaCompare imaging solution to a major Israeli software company, which company has been involved in the continued development of our technology. The purpose for this outsourcing was to conserve the Company’s capital resources. Certain key external consultants and medical professionals continue to assist and serve the Company as we advance the implementation of our marketing plan. As of December 31, 2017, and the date of this report, the Company has no employees on its payroll. However, certain liabilities with respect to payroll and severance payments remain outstanding. On January 29, 2018, the Company ceased its DermaCompare operations and is currently in the process of liquidating Emerald Israel. The Company commenced a new business operation in January 2018 under its newly-formed Israeli subsidiary, Virtual Crypto Technologies Ltd. To fund the new operations and to satisfy its existing debts, the Company raised approximately $1.9 million in the first quarter of 2018. Refer to subsequent event note 11. Going Concern: The Company has incurred significant operating losses and negative cash flows from operating activities in relation to its DermaCompare operations, since incorporation. The Company raised approximately $1.9 million in the first quarter of 2018 These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Such adjustments would have been required as of December 31 2017 had the Company not successfully completed the $1.9 million funding in the first quarter of 2018. Since the Company's balance sheet as of December 31 2017 is substantially comprised of financial instruments with carrying values that approximate liquidation values (cash and cash equivalents, short term accounts payable and accrued expenses, debt and related accrued interest presented at repayment amounts as well as derivative warrant liabilities with immaterial carrying and fair values), other than the reclassification of long term liabilities to short term, such adjustments would have been immaterial as of December 31 2017. Significant Accounting Policies Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of December 31, 2017 and December 31, 2016. Other Receivables The Company treats VAT refunds claimed, resulting from excess VAT paid over VAT received, as other receivables. Currency Translation and other Comprehensive Income The functional currency of the Virtual Crypto Technologies Inc. is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate. Fixed assets: New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 6 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place. Accounting For Obligations And Instruments Potentially To Be Settled In The Company’s Own Stock: We account for obligations and instruments potentially to be settled in the Company’s stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This guidance addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company’s own stock. Fair Value of Financial Instruments: FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2017 and 2016, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. The Company measures its derivative warrant liabilities at fair value at each period. The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Accounting For Convertible Debt Instruments We account for convertible debt instruments, which do not meet the definition of a derivative financial instrument per FASB ASC 815, Accounting for Derivative Financial Instruments, in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. This guidance addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Discount on the debt component resulting from allocation of proceeds to the equity component is amortized in the profit and loss statement as finance expense. Allocation of proceeds into equity and debt components of convertible notes issued together with other detachable financial instruments is performed, in relation to the proceeds allocated to the convertible notes, based on the relative fair value of such convertible notes and the other detachable financial instruments issued. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors (including employee stock options under the Company’s stock plans) based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award, net of estimated forfeitures. The Company estimates the fair value of stock options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company. Earnings per Common Share Basic net loss per share is computed by dividing net loss, as adjusted to include the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis. Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2017 and December 31, 2016, since all such securities have an anti-dilutive effect. Research and development expenses, net: Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. Income Taxes: We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Uncertain Tax Positions: When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Recent Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on its financial statements. Following are newly issued standards or material updates to the Company’s previous assessments from its Annual Report on Form 10-K for the fiscal year ended December 31, 2016: In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective with respect to the Company beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it does not expect the new standard to have a material impact on its consolidated financial statements. In February 2016, the FASB issued a new lease accounting standard requiring the recognition of lease assets and liabilities on the balance sheet. This standard is effective beginning in the first quarter of 2019; early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. As the Company currently is not a party to any leasing arrangement, it does not expect the new standard to have a material impact on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments.” With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented as an allowance rather than as a write-down. The update is effective beginning in the first quarter of 2020; early adoption is permitted. As the Company has insignificant receivable balances, The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In May 2017, the FASB issued “ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting,” which clarifies when a change to terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the vesting condition, fair value or the award classification is not the same both before and after a change to the terms and conditions of the award. The new guidance is effective on a prospective basis beginning on January 1, 2018 and early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests With a Scope Exception”. The ASU makes limited changes to the Board’s guidance on classifying certain financial instruments as either liabilities or equity. The ASU’s objective is to improve (1) the accounting for instruments with “down-round” provisions and (2) the readability of the guidance in ASC 480 on distinguishing liabilities from equity by replacing the indefinite deferral of certain pending content with scope exceptions. This standard is effective beginning in the first quarter of 2019; early adoption is permitted. The Company early adopted the standard, retrospectively, for each prior period presented in these financial statements.

Other Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2017
Receivables [Abstract]
Other Receivables	Note 2. Other Receivables. As of December 31, 2017, and December 31, 2016, the Company had other receivables of $12,222 and $9,356, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received from the Israeli government.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Note 3. Accounts Payable and Accrued Liabilities. As of December 31, 2017, and December 31, 2016 the Company had accounts payable and accrued liabilities of $445,653 and $198,795, respectively, which mainly represent accrued expenses such as accrued vacation and deferred salary (see Note 8 for further details).

Employees Payable

Employees Payable	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Employees Payable	Note 4. Employees Payable. As of December 31, 2017, and 2016, the total amount owing to employees was $98,476 and $161,341. The amount owing as of December 31, 2017 includes amounts owing to employees in respect of the litigation against Emerald Israel. Reference is made to Note 8 below.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	Note 5. Notes Payable Notes payable and accrued interest as of December 31, 2017 and 2016 are as follows: December 31, 2017 December 31, 2016 Principle $ 920,484 $ 745,860 Discount - (306,529) Accrued interest 71,162 32,768 Total 991,646 472,099 Issuances of convertibles notes during 2016 and 2017 On March 24, 2016, a convertible note payable and Class A warrants to purchase 187,500 common shares were issued to GoldMed Ltd for a consideration of $75,000 The note bears interest at 8% per annum and is convertible through March 23, 2017. The exercise price of the warrant is $0.80 and expires 12 months after issuance. The warrants and the beneficial conversion feature were valued at $75,000, which resulted in a $75,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On April 11, 2016, a convertible note payable and Class A warrants to purchase 200,000 common shares were issued to Maz Partner. The note bears interest at 8% per annum and is convertible through April 10, 2017. The exercise price of the warrant is $0.80 and expires 12 months after issuance. The warrants and the beneficial conversion feature were valued at $80,000, which resulted in a $80,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On June 20, 2016, a convertible note payable and Class A warrants to purchase 1,000,000 common shares and Class B warrants to purchase 1,000,000 common shares were issued to Alpha Anstalt Capital (“Alpha”). The note bears interest at 8% per annum and is convertible through June 19, 2017. The exercise price of the Class A warrants is $0.80 and expires 12 months after issuance and the exercise price of Class B warrants is $0.80 and expires 60 months after issuance. The warrants and the beneficial conversion feature were valued at $440,000, which resulted in a $440,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On June 30, 2016, a convertible note payable and Class A warrants to purchase 100,000 common shares were issued to Ilan Malka. The note bears interest at 8% per annum and is convertible through June 29, 2017. The exercise price of the warrant is $0.80. The warrants and the embedded beneficial conversion feature were valued at $40,000, which resulted in a $40,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On July 7, 2016, a convertible note payable and Class A warrants to purchase 250,000 common shares and Class B warrants to purchase 250,000 were was issued to Firstfire Global Opportunities Fund LTC (“Firstfire”). The exercise price of the Class A warrants is $0.80 and expires 12 months after issuance and the exercise price of Class B warrants is $0.80 and expires 60 months after issuance. The warrants and the beneficial conversion feature were valued at $100,000, which resulted in a $100,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. The note bears interest at 8% per annum and is convertible through July 6, 2017. The terms of the convertibles note and warrants to Alpha Capital and Firstfire Global Opportunities Fund LTC The conversion price of the loans and the exercise price of Class A warrants and Class B warrants issued to Alpha and Firstfire, which had an exercise price of $0.80, were adjusted to $0.14, based on the Company’s share price on the 275 th In July 2016, the Company granted an option to Alpha and Chi Squared (the “Alpha Chi Option”) to purchase Notes for an aggregate of up to $385,000 (up to $350,000 for Alpha and up to $35,000 for Chi Squared Capital Inc.) (“Option Notes”) and Warrants (“Option Warrants”) substantially identical to the Notes and Warrants issued. The Company accounts for the Alpha Chi Option as derivative liabilities that are measured at their far value at each period end as further detailed below. The above-referenced convertible notes were due during 2017. A settlement agreement was reached with Alpha and Chi Squared Capital Inc. on August 7, 2017, as described below, and agreements were reached with other convertible note holders in 2018 as detailed in Note 11, Subsequent Events. Settlement Agreement Effective August 7, 2017, the Company entered into the settlement agreement with Alpha and Chi Squared Capital Inc. as a result of the fact that Alpha and Chi Squared had taken the position that certain defaults may have occurred as a result of actions and/or inactions by the Company with respect to the Company’s obligations under convertible notes (the “Notes”) issued during 2016, which the Company did not deem to be defaults (the “Settlement Agreement”). Pursuant to the Settlement Agreement, the Notes, which had originally provided for a maturity date of June 19, 2017 and were in the original principal amounts of $400,000 and $40,000, respectively, were extended until June 19, 2019, in consideration for which the Company agreed to an increase in the principal amounts to $551,600 and $55,160, respectively, both of which retain the adjusted conversion price of $0.14, calculated in accordance with the terms of the original Notes. Such conversion price is subject adjustments in the event of future financing at a price of less than $0.14 per share. As a further part of the settlement, the Company agreed to issue Alpha and Chi Squared a total of 528.82 newly authorized shares of Series A Convertible Preferred Stock having a stated value and liquidation preference of $1,000 per share, and are convertible into a total of 3,778,647 shares based upon a conversion price of $0.14 per share, subject to adjustment in the event of a future financing such that the amount of ordinary shares to be issued pursuant to conversion of Series A Convertible Preferred Stock will represent the value of $1,000, per 1 Series A Convertible Preferred Stock, based on a conversion price which is identical to the ordinary share price at which securities are offered in such future financing. The Series A Convertible Preferred Stock shall be entitled to receive dividends on the same basis as Ordinary Shares and shall have no voting rights. As part of the Settlement Agreement, the Company extended the Alpha Chi Option to July 15, 2018. The settlement was accounted for as extinguishment of the pre-settlement notes and re issuance of the Notes and Series A Convertible Preferred Stock. As a result of the Settlement Agreement, the Company recorded a charge to general and administrative expenses in the Statement of Operation Losses of $440,684 representing the penalties and liquidation damages portion of the above-mentioned provision, and $219,276 was charged to finance expenses in the Statement of Operating Losses. The Series A Convertible Preferred Stock were recorded in shareholders’ equity at their fair value at the effective date of the settlement. As the Company concluded the conversion feature embedded in the amended notes is not a beneficial conversion feature pursuant to the provisions of ASC 470-20 (“Debt with Conversion and Other Options”), the post amendment carrying amount of the convertible notes, which was based on the fair value of the convertible notes at the effective date of the settlement, was recorded in liabilities in its entirely. The Company accounts for options to purchase convertible notes and warrants (refer to the Alpha Chi Option above) as derivative liabilities that are measured at their far value at each period end, in accordance with ASC 815 (“Derivatives and Hedging”). The Company uses directly observable inputs as well as significant unobservable inputs in the valuation of these derivative liabilities (level 3 measurements). The inputs used in the valuation are risk free interest rate, expected volatility, expect option term, expected dividend yield and Company specific discount rate. The fair value of the derivative liabilities at December 31, 2017, as well prior to and following the effective date of the aforementioned settlement, was immaterial. The fair value of the derivative liabilities as of December 31, 2016 was $336,272. Finance expense from revaluation of the derivative liabilities included in the Company’s statement of operations was $336,272 for the year ended December 31 2016 and finance income was $336,272 for the year ended December 31, 2017. Non-convertible note On July 8, 2014, the Company issued a convertible note to Axel Springer Plug & Play Accelerator GmbH in the amount of $29,719. Accrued interest as of December 31, 2017 amounted to $3,316. In terms of the original agreement, as of December 31, 2017 and 2016, the convertible note is no longer convertible.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	Note 6. Stockholders’ Equity. Shares of common stock confer upon their holders the right to receive notice to participate and vote in general meetings of shareholders of the Company, the right to receive dividends, if declared, and the right to receive a distribution of any surplus of assets upon liquidation of the Company. Preferred shares confer upon their holders the right to receive dividends when paid to holders of common stock of the Company on an as-converted basis, and the right to receive a distribution of any surplus of assets upon liquidation of the Company before any distribution or payment shall be made to the holders of any common stock. The following table summarizes information of outstanding warrants issued to investors and consultants in exchange for their services as of December 31, 2017: Warrants Warrant Term Exercise Price Exercisable Investors - Class A Warrants 6,334,626 1 year $ 0.14-0.80 6,334,626 Investors - Class B Warrants 5,400,478 5 years $ 0.14 5,400,478 Alimi Ahmed - Class E Warrants (1) 900,000 (1) $ 0.0001 900,000 (1) During 2015, a total of 2,700,000 Class E Warrants were issued by the Company to Lior Wayn pursuant to the terms of the Share Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the “Tranches”) at an exercise price of $0.0001 per Share, subject to and within 45 days of the Company achieving the milestones defined in the Share Exchange Agreement. On December 16, 2016, the Company terminated Lior Way’s employment agreements with the Company and Emerald Israel, and his removal as an executive officer and director. During 2017, Mr. Wayn transferred, sold and assigned his 5,212,878 shares of the Company’s common stock and 900,000 Class E Warrants that were fully-vested to an entity controlled by Mr. Alimi Ahmed, then a member of the Company’s Board of Directors. Effective as of December 31, 2016, the remaining 1,800,000 Class E Warrants that had been issued to Mr. Wayn were canceled. Issuances of Common Stock and Warrants during 2016 and 2017 Certain warrants were issued together with convertible notes, as detailed in Note 6. On January 26, 2016 and March 17, 2016, the Company issued 125,000 common shares to one service provider and 50,000 common shares to two service providers, respectively, for services valued at a total value of $251,250, arrived at using the stock price on date of grant of $1.75 and $0.65, respectively. On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00. On January 26, 2016, consultants that were previously issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share, exercised the warrants on a cashless basis resulting in 1,928,572 shares issued with no additional related expense booked. On May 5, 2016, the Company issued 150,000 shares to one service provider for services valued at a total value of $105,000, arrived at using the stock price on date of grant of $0.7. On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at a total value of $29,584, arrived at using the stock price on date of grant of $0.71. On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at a total value of $102,000, arrived at using the stock price on date of grant of $0.68. On June 28, 2016, the Company issued 175,000 shares to three service providers for services valued at a total value of $122,500, arrived at using the stock price on date of grant of $0.7. On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at a total value of $226,666, arrived at using the stock price on date of grant of $0.68. On July 1, 2016, the Company issued 300,000 shares to one service provider for service valued at a total value of $213,000 arrived at using the stock price on date of grant of $0.71. On July 1, 2016, the Company issued 6,767 shares to one service provider for service valued at a total value of $3,587 arrived at using the stock price on date of grant of $0.53. On August 4, 2016, the Company issued 31,250 shares to one service provider for service valued at a total value of $15,313, arrived at using the stock price on date of grant of $0.49. The total value of the services provided in respect of the above-mentioned share issuances between May 2016 and June 2016 were charged to general and administrative expenses in the Statement of Comprehensive Loss. On November 10, 2016, the Company issued 119,000 units to Guy Shalom in total amount of $47,600. Each unit consist 119,000 Class A Warrants exercisable for a two-year period in exercise price of $0.80 and 119,000 common shares. On February 24, 2017, Publicis Groupe 90 (“Publicis 90”) invested 500,000 Euros or approximately U$526,000 and the Registrant accepted a Reg S Subscription Agreement from Publicis 90 in consideration for the issuance to Publicis 90 of 1,315,563 restricted shares of the Registrant’s common stock at a subscription price of $0.40 per share. The issuance was made in reliance upon the exemptions provided in Section 4(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation S promulgated by the SEC under the Act. On April 25, 2017, a holder of a convertible note in the principal amount of $100,000 issued in July 2016, converted $10,400 into 74,572, shares based on an adjusted conversion price of $0.14. The conversion price was adjusted on March 22, 2017 pursuant to the provisions of the 2016 Secured Convertible Note Agreement. On June 12, 2017, certain warrant holders holding 1,100,000 Class A Warrants and 1,100,000 Class B Warrants, elected to exercise certain warrants on a cashless basis. In accordance with the 2016 Secured Convertible Note Agreement the Class A warrants and Class B warrants were increased to 5,665,626 each, based on an adjusted share price of $0.14 per share and 3,451,490 Class B Warrants were converted to 1,096,395 shares at $0.14 per share. The exercise price and amount of shares issued were adjusted on March 22, 2017. On June 12, 2017, the Company completed the issuance of 125,000 shares of the Company’s common stock to Alpha pursuant to the Company’s agreement with Alpha in the prior year. In July and August 2017, the Company received $80,000 in respect of 571,429 units to two accredited investors for $0.14 per unit. Each unit consist (i) 571,429 shares at a price of $0.14 per share, (ii) 571,429 Class H warrants exercisable for a one-year period in exercise price of $0.14, and (iii) 571,429 Class I warrants exercisable for a two-year period. As of December 31, 2017, the Company had not issued the shares or the warrants to the accredited investors as such, the proceeds were recorded as Receipts on Account of shares in the Company’s shareholders equity statement. During 2017, Class A warrants issued during 2015 which were exercisable to acquire 4,149,719 shares, expired. During 2016, the Class C warrants issued during 2014, expired. Recent Option Grants During the fiscal year ended December 31, 2017, the Company had outstanding awards for stock options under its 2017 Stock Incentive Plan (the “Plan”). The Plan, which was approved by the Board of Directors on December 1, 2017 and provides for the grant of up to 2 million shares to eligible participants bearing such terms and conditions, including but not limited to vesting provisions, exercise price(s) and other terms as the Board of Directors may reasonably determine from time to time, expires on November 30, 2023. Options granted under the Plan may be exercised on a cash or cashless basis, and the number of shares eligible for grant under the Plan may be increased, and the option exercise price(s) and vesting terms may the adjusted by, the Board of Directors, subject to provisions of the Plan and applicable laws and rules. Any options under the Plans that are canceled or forfeited before expiration become available for future grants. The Board of Directors of the Company administers the Company’s stock incentive compensation and equity-based plans. On February 11, 2016, the Company’s board of directors approved a grant of 70,533 options to certain of its employees. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.01-$0.4 per share. As of December 31,2016, 47,133 options were fully-vested, and 31,500 options were canceled. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $21,798. On February 18, 2016, the Company’s board of directors approved a grant of 1,466,700 options to certain of its employees and consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.01- $0.4 per share. As of December 31,2016, all the options were fully vested. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $1,389,614. On May 5, 2016, the Company’s board of directors approved a grant of 93,750 options to certain of consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.001 per share. As of December 31, 2016, all the options were fully vested. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $61,455. On October 1, 2016, the Company’s board of directors approved a grant of 2,514,500 options to certain of its executive, director and consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.001- $0.40 per share. As of December 31, 2016, 1,111,500 options were fully vested and $450,000 thousands were canceled. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $396,222. On November 3, 2016, the Company’s board of directors approved a grant of 339,000 options to certain of its employees. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.2-$0.4 per share. As of December 31,2016, 139,000 options were fully vested. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $40,747. A summary of the Company’s activity related to options to employees, executives, directors and consultants and related information is as follows: For the year ended December 31, 2017 For the year ended December 31, 2016 Amount of options Weighted average exercise price Aggregate intrinsic value Amount of options Weighted average exercise price Aggregate intrinsic value $ $ $ $ Outstanding at beginning of year 4,193,397 0.11 561,280 0.0666 Granted 5,440,483 0.1336 Exercised - - (697,086 ) - Cancelled (4,130,397 ) (0.11 ) (550,000 ) (0.3956 ) Outstanding at the end of year 62,500 0.01 4,193,397 0.11 1,006,415 Vested and expected-to-vest at end of period 62,500 0.01 - 3,288,062 0.11 789,134 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value of the Company’s common shares on December 31, 2017 and December 31, 2016 respectively and the exercise price, multiplied by the number of in-the-money stock options on those dates) that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates. The stock options outstanding as of December 31, 2017, and December 31, 2016, have been separated into exercise prices, as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, 2017 2016 2017 2016 2017 2016 0.4 - 1,208,600 - 9.25 - 1,208,600 0.2 - 1,870,000 - 9 - 1,870,000 (*) 62,500 1,114,797 8.25 9.25 62,500 1,114,797 62,500 4,193,397 8.25 9.25 4,193,397 4,193,397 (*) 0.01 or less Compensation expense recorded by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended December 31, 2017 and 2016 was $76,616 and $2,028,805, respectively and are included in General and Administrative expenses in the Statements of Operations The fair value of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions: Years ended December 31, 2017 2016 Expected volatility (* ) 157 % Risk-free interest (* ) 0.69 % Dividend yield (* ) 0 % Expected life of up to (years) (* ) 6.0 (*) There were no options granted during the year ended December 31, 2017.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 7. Related Party Transactions. Other than transactions and balances related to cash and share based compensation to officers and directors and other than the issues of convertible debt and warrants to Alpha, the Company did not have any transactions and balances with related parties and executive officers during 2017 and 2016 other than an amount of $82,331 and $125,896 as of December 31, 2017 and 2016, respectively owed to the Company’s chairman in respect of Company expenditures paid by him on behalf of the Company.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies The Company received grants to fund research and development projects from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obligated to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% of sales and the total royalties will not exceed the amount of the grants received. As of December 31, 2016, total grants received amounted approximately $222 thousands. The obligation to pay royalties is contingent upon the successful outcome of the Company’s research and development projects and the attainment of sales. The Company has no obligation to pay royalties, if sales are not generated, and if the research and development project fails. In April 2017, a lawsuit was filed with the Tel Aviv court by Emerald’s former CEO and founder, claiming certain damages to the total amount of $100,000, under the assertion of wrongful dismissal by the Company. The Company believes these claims to be unsubstantiated and wholly without merit and intends to defend itself against these claims. The Company believes that there is a less than 50% chance of his claim being successful. Accordingly, no provision was recorded in regards to this claim. In December 2017, a liquidation request was filed with the Tel Aviv court by a group of former Company’s employees under the assertion of delay of pay and insolvency. On December 20, 2017, a hearing discussion took place according to which the court decision that the Company shall settle its pension debts to the former employees within 21 days and settle its severance debts to them in 60 days, otherwise a winding-up order could be given. The amounts being claimed by the former employees are less than $96,000 and are included in current liabilities. The Company is seeking to identify potential acquired of Emerald Israel, but as of the date of this report has been unsuccessful and therefore the Company believes that the Court will place Emerald Israel in liquidation.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 Income Taxes. The Company is subject to income taxes under the Israeli and U.S. tax laws: Corporate tax rates The Company is subject to Israeli corporate tax rate of 25% in 2016, 24% in 2017 and 23% from 2018. The maximum statutory federal tax rate in the US in 2017 and 2016 is 35%. The Company is not subject to current federal taxes, as it has incurred losses in 2016 and 2017. As of December 31, 2017, the Company generated net operating losses in Israel of approximately $3,193,927, which may be carried forward and offset against taxable income in the future for an indefinite period. As of December 31, 2017, the Company generated net operating losses in the U.S. of approximately $15,150,925. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. As of December 31, 2017 As of December 31, 2016 Net loss carry-forward $ 18,344,852 $ 17,155,076 Total deferred tax assets 3,916,297 5,730,945 Valuation allowance (3,916,297 ) (5,730,945 ) Net deferred tax assets $ - $ - On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law in the United States. The Tax Act, among other provisions, introduces changes in the U.S corporate tax rate, business related deductions and credits, and has international tax consequences for companies that operate globally. Most of the changes introduced in the Tax Act are effective beginning on January 1, 2018. As a result of the tax act the maximum statutory federal tax rate was reduced to 21% starting on January 1, 2018. The other effects of the Tax Act provisions are still being identified and evaluated by the Company.

Restatement

Restatement	12 Months Ended
	Dec. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Restatement	Note 10 -Restatement Options to Purchase Convertible Notes and Warrants As described in Note 5, during July 2016 the Company issued Alpha and Chi Squared, an option to (the “Option”) to purchase an aggregate of up to $385,000 (up to $350,000 for Alpha and up to $35,000 for Chi Squared) of Notes (“Option Notes”) and Warrants (“Option Warrants”) substantially identical to the Notes and Warrants issued pursuant to Alpha and Chi in June 2016. As part of the Settlement Agreement concluded in August 2017 (see note 5), The Option was extended through to July 15, 2018. As of the date of the Settlement Agreement, and as of December 31, 2017, the fair value of the Option is nil. The Option, as described above does not meet the scope exception of ASC 815 (“Derivatives and Hedging”) and as such, the Option should have been measured at its fair value at the effective date of the grant date and at each subsequent reporting date. The Company erroneously did not record the fair value of the Option at the issuance date and at December 31, 2016. The fair value of the Option at issuance date and as of December 31, 2016 was $1,049,953 and $336,272, respectively. The following tables present the restated financial statements line items: Emerald Medical Applications Corp. Balance Sheet As of December 31, 2016 As Reported Adjustments As Restated Liabilities Derivative liability - 336,272 336,272 Accumulated deficit 14,670,241 336,272 15,046, 513 Total shareholders’ deficit (900,627 ) 336,272 (1,236,899 ) Emerald Medical Applications Corp. Statement of Operations For the year ended December 31, 2016 As Reported Adjustments As Restated Total finance income (expense) (414,190 ) (336,272 ) (750,462 ) Net Loss (5,808,925 ) (336,272 ) (6,145,197 ) Down Round Feature Included in Convertible Notes and Warrants As described in Note 5, the Company’s convertible notes and warrants issued in 2016 to Alpha and Chi Squared and Firstfire contain a down round adjustment feature which, according to US Gaap, requires such derivatives to be classified in liabilities and to be measured at their fair value at each cut of date. Such derivative liabilities, with a fair value of $567 thousand as of December 31, 2016 were erroneously not included in the Company’s December 31 2016 balance sheet. The Company early adopted ASU 2017-11, Part I (“Accounting for Certain Financial Instruments with Down Round Features”), issued in July 2017, which makes certain changes in relation to classifying certain financial instruments as either liabilities or equity such that the aforementioned derivatives are no longer precluded from being recorded in equity. The Company adopted the standard retrospectively for all prior periods presented in these interim financial statements such that December 31 2016 comparison information included in these financial statements is identical to the December 31 2016 financial information included in the Company’s original 2016 annual 10-K filing.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 11. Subsequent Events. Cessation of Operations On January 29, 2018, the Company determined to cease it DermaCompare operations and a trustee is currently in the process of liquidating Emerald Israel to satisfy its debts. New Business Developments On January 17, 2018, the Company formed a new wholly owned subsidiary, Virtual Crypto Technologies Ltd. (the Subsidiary”), to develop and market software and hardware products facilitating, allowing and supporting purchase and/or sale of cryptocurrencies through ATMs, tablets, PCs and/or mobile devices. On January 23, 2018, the Subsidiary entered into a binding term sheet with Chiron Refineries Ltd. (“Chiron”), a public company listed on the Tel-Aviv Stock Exchange (TASE: CHR). Pursuant to the Term Sheet, they shall act as a distributer in the territory of the Republic of Turkey, including the territory of Turkish Republic of Northern Cyprus (the “Territory”); and (ii) the shall have the right to appoint sub-distributors within the Territory. The appointment of the Distributor is subject to the payment by the Distributor to our Subsidiary of US$250,000 (the “Appointment Fee”). An amount of $150,000 of the total Appointment Fee shall be deemed an advance payment by the Distributor, made on account of future purchases of our Products and related services. The Company further granted the Distributor an option, exercisable by the Distributor within 12 months from the date on which the ATM Product, including the related software and hardware, is fully tested and ready for installation and operation, to be appointed as an exclusive distributor of the Products for the Federal Republic of Nigeria. If the option is exercised, the Distributor shall pay the Subsidiary an appointment fee not higher than $250,000. Issuance of convertible notes in 2018. From January 16 through January 23, 2018, the Company received the aggregate amount of $100,000 from “accredited investors” in consideration for the issuance of convertible promissory notes (the “Notes”) bearing: (i) interest at the rate of 1% per annum; and (ii) a conversion price of $0.01 per share. On December 19, 2017, the Company approved, subject to a future sale by the “Sellers,” (as defined below) to sell their convertible loans, loans, and warrant to certain third-party investors and in connection therewith, to: (i) amend the exercise price of warrants granted to Alpha, Chi Squared Capital, Firstfire, Goldmed Ltd, Ilan Malca and Maz Partners (the “Sellers”) to $0.01, (ii) to amend the conversation price of convertible notes granted to Sellers to $0.01 and (iii) to amend the interest rate to 1% per annum. On January 24, the Sellers sold their loans totaling $956,209 to the new third-party investors, and $73,000 of such loans were converted at $0.01 per shares into 7,300,000 ordinary shares of the Company. Also, on March 19, 2018, a further $9,218 into 921,800 shares, based upon the note conversion price of $0.01 per share. On January 26, 2018 the company signed a consulting agreement with Maz Partners, pursuant to which they are to provide investment and corporate finance advise in consideration for 200,000 Class H warrants. Each Class H warrant is execrable into one share at $0.14 per share and the warrants expire each exercisable into one shares. The period of the agreement is two years the effective date. Equity raise from the sale of units in 2018. From January 31 through February 13, 2018, the Company received the aggregate amount of $1,375,700 from “accredited investors” in consideration for the issuance of 19,647,856 units (the “Units”) at an offering price of $0.07 per Unit, each Unit consisting of: (i) one (1) share of common stock (the “Shares”); and (ii) one (1) common stock purchase warrant exercisable for a period of twenty-four (24) months to purchase one (1) additional Share at an exercise price of $0.14. (the “$0.07 Unit Offering”). The offer and sale of the Units, without registration under the Securities Act of 1933, as amended (the “Act”), was made in reliance upon the exemption provided Regulation S and Regulation D promulgated by the Securities and Exchange Commission under the Act. An additional 13 “accredited investors” under the $0.07 Unit Offering, who subscribed during the period set forth above, submitted their subscription proceeds after February 16, 2018 and, as a result, the Registrant issued an additional 3,928,571 restricted shares through March 13, 2018 and, in connection therewith, the Registrant received additional subscription proceeds of $277,100. On February 8, 2018 the Company issued 571,429 shares to two accredited investors in respect of $80,000 which was received in 2017 – see note (6). On March 12, 2018, the Company issued a total of 2,600,000 restricted shares to certain consultants in connection with services rendered during the first quarter of 2018 which shares were valued at $676,000, based on the closing share price on the day prior to the issuance. On March 20, 2018, the Company issued a total of 1,092,500 restricted shares as follows: (i) 62,500 restricted shares were issued to Guy Shalom, a resident of Israel, in consideration for the exercise of a stock option at an exercise price of $0.01 per share, which options were granted in connection with a services rendered in October 2016; (ii) 300,000 restricted shares were issued to Yair Fudim, a resident of Israel, pursuant to a Services Agreement for serving as the Registrant’s CEO, which shares were valued at $0.01 per share; and (iii) 730,000 restricted shares were issued to Lyons Capital LLC, an accredited investor organized under the laws of the State of Florida, in connection with services under a six-month engagement letter/services agreement (“Engagement Letter”), which shares were valued at $124,100, based on the closing share price on the day prior to the Engagement Letter.

The Company and Significant A19

The Company and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of December 31, 2017 and December 31, 2016.
Other Receivables	Other Receivables The Company treats VAT refunds claimed, resulting from excess VAT paid over VAT received, as other receivables.
Currency Translation and Other Comprehensive Income	Currency Translation and other Comprehensive Income The functional currency of the Virtual Crypto Technologies Inc. is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.
Fixed Assets	Fixed assets: New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 6 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place.
Accounting for Obligations and Instruments Potentially to be Settled in the Company's Own Stock	Accounting For Obligations And Instruments Potentially To Be Settled In The Company’s Own Stock: We account for obligations and instruments potentially to be settled in the Company’s stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This guidance addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company’s own stock.
Fair Value of Financial Instruments	Fair Value of Financial Instruments: FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2017 and 2016, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. The Company measures its derivative warrant liabilities at fair value at each period. The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Accounting for Convertible Debt Instruments	Accounting For Convertible Debt Instruments We account for convertible debt instruments, which do not meet the definition of a derivative financial instrument per FASB ASC 815, Accounting for Derivative Financial Instruments, in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. This guidance addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Discount on the debt component resulting from allocation of proceeds to the equity component is amortized in the profit and loss statement as finance expense. Allocation of proceeds into equity and debt components of convertible notes issued together with other detachable financial instruments is performed, in relation to the proceeds allocated to the convertible notes, based on the relative fair value of such convertible notes and the other detachable financial instruments issued.
Share-based Compensation	Share-based compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors (including employee stock options under the Company’s stock plans) based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award, net of estimated forfeitures. The Company estimates the fair value of stock options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.
Earnings Per Common Share	Earnings per Common Share Basic net loss per share is computed by dividing net loss, as adjusted to include the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis. Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2017 and December 31, 2016, since all such securities have an anti-dilutive effect.
Research and Development Expenses, Net	Research and development expenses, net: Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses.
Income Taxes	Income Taxes: We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
Uncertain Tax Positions	Uncertain Tax Positions: When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on its financial statements. Following are newly issued standards or material updates to the Company’s previous assessments from its Annual Report on Form 10-K for the fiscal year ended December 31, 2016: In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective with respect to the Company beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it does not expect the new standard to have a material impact on its consolidated financial statements. In February 2016, the FASB issued a new lease accounting standard requiring the recognition of lease assets and liabilities on the balance sheet. This standard is effective beginning in the first quarter of 2019; early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. As the Company currently is not a party to any leasing arrangement, it does not expect the new standard to have a material impact on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments.” With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented as an allowance rather than as a write-down. The update is effective beginning in the first quarter of 2020; early adoption is permitted. As the Company has insignificant receivable balances, The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In May 2017, the FASB issued “ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting,” which clarifies when a change to terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the vesting condition, fair value or the award classification is not the same both before and after a change to the terms and conditions of the award. The new guidance is effective on a prospective basis beginning on January 1, 2018 and early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests With a Scope Exception”. The ASU makes limited changes to the Board’s guidance on classifying certain financial instruments as either liabilities or equity. The ASU’s objective is to improve (1) the accounting for instruments with “down-round” provisions and (2) the readability of the guidance in ASC 480 on distinguishing liabilities from equity by replacing the indefinite deferral of certain pending content with scope exceptions. This standard is effective beginning in the first quarter of 2019; early adoption is permitted. The Company early adopted the standard, retrospectively, for each prior period presented in these financial statements.

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Notes payable	Notes payable and accrued interest as of December 31, 2017 and 2016 are as follows: December 31, 2017 December 31, 2016 Principle $ 920,484 $ 745,860 Discount - (306,529) Accrued interest 71,162 32,768 Total 991,646 472,099

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Outstanding Warrants	The following table summarizes information of outstanding warrants issued to investors and consultants in exchange for their services as of December 31, 2017: Warrants Warrant Term Exercise Price Exercisable Investors - Class A Warrants 6,334,626 1 year $ 0.14-0.80 6,334,626 Investors - Class B Warrants 5,400,478 5 years $ 0.14 5,400,478 Alimi Ahmed - Class E Warrants (1) 900,000 (1) $ 0.0001 900,000 (1) During 2015, a total of 2,700,000 Class E Warrants were issued by the Company to Lior Wayn pursuant to the terms of the Share Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the “Tranches”) at an exercise price of $0.0001 per Share, subject to and within 45 days of the Company achieving the milestones defined in the Share Exchange Agreement. On December 16, 2016, the Company terminated Lior Way’s employment agreements with the Company and Emerald Israel, and his removal as an executive officer and director. During 2017, Mr. Wayn transferred, sold and assigned his 5,212,878 shares of the Company’s common stock and 900,000 Class E Warrants that were fully-vested to an entity controlled by Mr. Alimi Ahmed, then a member of the Company’s Board of Directors. Effective as of December 31, 2016, the remaining 1,800,000 Class E Warrants that had been issued to Mr. Wayn were canceled.
Summary of Employee Stock Option Activity	A summary of the Company’s activity related to options to employees, executives, directors and consultants and related information is as follows: For the year ended December 31, 2017 For the year ended December 31, 2016 Amount of options Weighted average exercise price Aggregate intrinsic value Amount of options Weighted average exercise price Aggregate intrinsic value $ $ $ $ Outstanding at beginning of year 4,193,397 0.11 561,280 0.0666 Granted 5,440,483 0.1336 Exercised - - (697,086 ) - Cancelled (4,130,397 ) (0.11 ) (550,000 ) (0.3956 ) Outstanding at the end of year 62,500 0.01 4,193,397 0.11 1,006,415 Vested and expected-to-vest at end of period 62,500 0.01 - 3,288,062 0.11 789,134
Schedule of Stock Options Outstanding Exercise Price Range	The stock options outstanding as of December 31, 2017, and December 31, 2016, have been separated into exercise prices, as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, 2017 2016 2017 2016 2017 2016 0.4 - 1,208,600 - 9.25 - 1,208,600 0.2 - 1,870,000 - 9 - 1,870,000 (*) 62,500 1,114,797 8.25 9.25 62,500 1,114,797 62,500 4,193,397 8.25 9.25 4,193,397 4,193,397 (*) 0.01 or less
Schedule of Fair Value Assumptions	The fair value of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions: Years ended December 31, 2017 2016 Expected volatility (* ) 157 % Risk-free interest (* ) 0.69 % Dividend yield (* ) 0 % Expected life of up to (years) (* ) 6.0 (*) There were no options granted during the year ended December 31, 2017.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	As of December 31, 2017 As of December 31, 2016 Net loss carry-forward $ 18,344,852 $ 17,155,076 Total deferred tax assets 3,916,297 5,730,945 Valuation allowance (3,916,297 ) (5,730,945 ) Net deferred tax assets $ - $ -

Restatement (Tables)

Restatement (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Schedule of Restated Financial Statements	The following tables present the restated financial statements line items: Emerald Medical Applications Corp. Balance Sheet As of December 31, 2016 As Reported Adjustments As Restated Liabilities Derivative liability - 336,272 336,272 Accumulated deficit 14,670,241 336,272 15,046, 513 Total shareholders’ deficit (900,627 ) 336,272 (1,236,899 ) Emerald Medical Applications Corp. Statement of Operations For the year ended December 31, 2016 As Reported Adjustments As Restated Total finance income (expense) (414,190 ) (336,272 ) (750,462 ) Net Loss (5,808,925 ) (336,272 ) (6,145,197 )

The Company and Significant A24

The Company and Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Funding description	Such adjustments would have been required as of December 31 2017 had the Company not successfully completed the $1.9 million funding in the first quarter of 2018.
Cash equivalents
Property and equipment estimated useful lives	6 years
Tax benefit percentage	Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.
First Quarter of 2018 [Member]
Raised capital	$ 1,900,000

Other Receivables (Details Narr

Other Receivables (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Other receivables	$ 12,222	$ 9,356

Accounts Payable and Accrued 26

Accounts Payable and Accrued Liabilities (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	$ 445,653	$ 198,795

Employees Payable (Details Narr

Employees Payable (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Total amount owing to employees	$ 98,476	$ 161,341

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)

Jul. 07, 2016

Jun. 30, 2016

Jun. 20, 2016

Apr. 11, 2016

Mar. 24, 2016

Jul. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Jun. 12, 2017

Jan. 26, 2016

Jul. 08, 2014

Reduction of debt discount

$ (306,529)

Debt instrument principal amount

$ 100,000

$ 920,484

$ 745,860

Preferred stock, shares authorized

10,000,000

10,000,000

General and administrative expenses

$ (911,581)

$ (3,749,867)

Fair value of the derivative liabilities

567

Derivative liability

336,272

[1]

Accrued interest

$ 3,316

Axel Springer Plug [Member]

Debt instrument principal amount

$ 29,719

Settlement Agreement [Member]

Conversion price of the loan

$ 0.14

Debt instrument principal amount

$ 400,000

40,000

Debt instrument, maturity date

Jun. 19, 2019

Increase in the principal amounts

$ 551,600

55,160

Conversion price is subject adjustments event of future financing

$ 0.14

Fair value of the derivative liabilities

336,272

Derivative liability

$ 336,272

Finance income

$ 336,272

Class A Warrant [Member]

Warrants to purchase share of common stock

1,100,000

Class B Warrant [Member]

Warrants to purchase share of common stock

1,100,000

Share price

$ 0.40

GoldMed Ltd [Member] | Class A Warrant [Member]

Warrants to purchase share of common stock

187,500

Consideration amount

$ 75,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Warrant term description

expires 12 months after issuance

Beneficial conversion feature

$ 75,000

Reduction of debt discount

$ 75,000

Maz Partner [Member] | Class A Warrant [Member]

Warrants to purchase share of common stock

200,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Warrant term description

expires 12 months after issuance

Beneficial conversion feature

$ 80,000

Reduction of debt discount

$ 80,000

Alpha Anstalt Capital [Member] | Class A Warrant [Member]

Warrants to purchase share of common stock

1,000,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Warrant term description

expires 12 months after issuance

Beneficial conversion feature

$ 440,000

Reduction of debt discount

$ 440,000

Alpha Anstalt Capital [Member] | Class B Warrant [Member]

Warrants to purchase share of common stock

1,000,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Warrant term description

expires 60 months after issuance

Beneficial conversion feature

$ 440,000

Reduction of debt discount

$ 440,000

Ilan Malka [Member] | Class A Warrant [Member]

Warrants to purchase share of common stock

100,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Beneficial conversion feature

$ 40,000

Reduction of debt discount

$ 40,000

Firstfire Global Opportunities Fund LTC [Member] | Class A Warrant [Member]

Warrants to purchase share of common stock

250,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Warrant term description

expires 12 months after issuance

Beneficial conversion feature

$ 100,000

Reduction of debt discount

$ 100,000

Conversion price of the loan

$ 0.80

Share price

$ 0.14

Firstfire Global Opportunities Fund LTC [Member] | Class B Warrant [Member]

Warrants to purchase share of common stock

250,000

Debt interest rate

8.00%

Warrant Exercise Price

$ 0.80

Warrant term description

expires 60 months after issuance

Reduction of debt discount

$ 100,000

Conversion price of the loan

$ 0.80

Share price

$ 0.14

Alpha and Chi Squared [Member] | Settlement Agreement [Member] | Series A Convertible Preferred Stock [Member]

Conversion price of the loan

$ 0.14

Preferred stock, shares authorized

528.82

Stated value and liquidation preference

$ 1,000

Conversion amount

3,778,647

General and administrative expenses

440,684

Finance expenses

$ 219,276

Alpha and Chi Squared [Member] | Maximum [Member]

Stock granted for purchase notes

385,000

Alpha Capital Anstalt [Member] | Maximum [Member]

Stock granted for purchase notes

350,000

Chi Squared Capital Inc [Member] | Maximum [Member]

Stock granted for purchase notes

$ 35,000

Play Accelerator GmbH [Member]

Debt instrument principal amount

$ 29,719

[1]

Restated - see Note 10.

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Jul. 31, 2016
Debt Disclosure [Abstract]
Principle	$ 920,484	$ 745,860	$ 100,000
Discount		(306,529)
Accrued interest	71,162	32,768
Total	$ 991,646	$ 472,099

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative)	Aug. 31, 2017USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Jun. 12, 2017$ / sharesshares	Apr. 25, 2017USD ($)$ / sharesshares	Feb. 24, 2017USD ($)$ / sharesshares	Nov. 10, 2016USD ($)$ / sharesshares	Nov. 03, 2016$ / sharesshares	Oct. 01, 2016$ / sharesshares	Aug. 04, 2016USD ($)$ / sharesshares	Jul. 02, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 28, 2016USD ($)$ / sharesshares	May 18, 2016USD ($)$ / sharesshares	May 10, 2016USD ($)$ / sharesshares	May 05, 2016USD ($)$ / sharesshares	Mar. 17, 2016USD ($)$ / sharesshares	Feb. 18, 2016USD ($)$ / sharesshares	Feb. 11, 2016$ / sharesshares	Jan. 26, 2016USD ($)$ / sharesshares	Aug. 31, 2017USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Feb. 24, 2017EUR (€)	Jul. 31, 2016USD ($)	Jun. 20, 2016$ / sharesshares
Warrants issued																						4,149,719
Stock issued during period, value, new issues | $
Convertible note principal amount | $																						$ 920,484	$ 745,860		$ 100,000
Debt converted amount | $				$ 10,400
Debt converted shares				74,572
Price per share | $ / shares				$ 0.14
Number of shares granted																							5,440,483
Number of options canceled																						4,130,397	550,000
Compensation expenses | $																						$ 76,616
2017 Stock Incentive Plan [Member]
Number of common stock shares issued																						2,000,000
Stock option plan expire																						Nov. 30, 2023
Two Accredited Investors [Member]
Warrants exercisable | $	$ 571,429	$ 571,429																		$ 571,429	$ 571,429
Warrant Exercise Price | $ / shares	$ 0.14	$ 0.14																		$ 0.14	$ 0.14
Proceeds from related party | $																				$ 80,000	$ 80,000
1st Accredited Investors [Member]
Warrants exercisable | $	$ 571,429	$ 571,429																		$ 571,429	$ 571,429
Warrant Exercise Price | $ / shares	$ 0.14	$ 0.14																		$ 0.14	$ 0.14
2nd Accredited Investors [Member]
Warrants exercisable | $	$ 571,429	$ 571,429																		$ 571,429	$ 571,429
Warrant Exercise Price | $ / shares	$ 0.14	$ 0.14																		$ 0.14	$ 0.14
Viva Technology Paris [Member]
First prize at the inaugural edition | $					$ 526,000
Viva Technology Paris [Member] | EUR [Member]
First prize at the inaugural edition | €																								€ 500,000
Publicis 90 [Member] | Reg S Subscription Agreement [Member]
Subscription price per share | $ / shares					$ 0.40
Number of restricted shares issued					1,315,563
Alpha Anstalt Capital [Member]
Number of common stock shares issued			125,000
Class B Warrant [Member]
Subscription price per share | $ / shares																			$ 0.40
Warrants issued																			2,500,000
Warrants exercisable period																			2 years
Number of warrant shares			1,100,000
Debt converted shares			1,096,395
Number of shares converted			3,451,490
Class B Warrant [Member] | 2016 Secured Convertible Note Agreement [Member]
Warrant Exercise Price | $ / shares			$ 0.14
Number of warrant shares			5,665,626
Class B Warrant [Member] | Alpha Anstalt Capital [Member]
Warrant Exercise Price | $ / shares																										$ 0.80
Number of warrant shares																										1,000,000
Warrant [Member]
Warrants issued																			1,928,572
Class A Warrant [Member]
Number of warrant shares			1,100,000
Class A Warrant [Member] | 2016 Secured Convertible Note Agreement [Member]
Warrant Exercise Price | $ / shares			$ 0.14
Number of warrant shares			5,665,626
Class A Warrant [Member] | Alpha Anstalt Capital [Member]
Warrant Exercise Price | $ / shares																										$ 0.80
Number of warrant shares																										1,000,000
Class H warrant [Member] | Two Accredited Investors [Member]
Warrants exercisable | $	$ 571,429	$ 571,429																		$ 571,429	$ 571,429
Warrant term																				1 year	1 year
Warrant Exercise Price | $ / shares	$ 0.14	$ 0.14																		$ 0.14	$ 0.14
Class I warrant [Member] | Two Accredited Investors [Member]
Warrants exercisable | $	$ 571,429	$ 571,429																		$ 571,429	$ 571,429
Warrant term	2 years	2 years
Warrant Exercise Price | $ / shares	$ 0.14	$ 0.14																		$ 0.14	$ 0.14
One Service Provider [Member]
Stock issued during period, shares, issued for services									31,250		333,333		150,000	41,667	150,000	125,000			125,000
Stock issued during period, value, issued for services | $									$ 15,313		$ 226,666		$ 102,000	$ 29,584	$ 105,000	$ 251,250			$ 251,250
Subscription price per share | $ / shares									$ 0.49		$ 0.68		$ 0.68	$ 0.71	$ 0.7	$ 1.75			$ 1.75
Two Service Provider [Member]
Stock issued during period, shares, issued for services																50,000			50,000
Stock issued during period, value, issued for services | $																$ 251,250			$ 251,250
Subscription price per share | $ / shares																$ 0.65			$ 0.65
Three Acting Directors [Member]
Stock issued during period, shares, issued for services																	1,195,000
Stock issued during period, value, issued for services | $																	$ 1,194,403
Subscription price per share | $ / shares																	$ 1
Three Service Provider [Member]
Stock issued during period, shares, issued for services												175,000
Stock issued during period, value, issued for services | $												$ 122,500
Subscription price per share | $ / shares												$ 0.7
One Service Provider A [Member]
Stock issued during period, shares, issued for services										6,767
Stock issued during period, value, issued for services | $										$ 3,587
Subscription price per share | $ / shares										$ 0.53
Guy Shalom [Member]
Number of common stock shares issued						119,000
Stock issued during period, value, new issues | $						$ 47,600
Warrants exercisable | $						$ 119,000
Warrant term						2 years
Warrant Exercise Price | $ / shares						$ 0.80
Number of warrant shares						119,000
Employees [Member] | Recent Option Grants 1 [Member]
Number of shares granted																		70,533
Exercise price range, lower range limit | $ / shares																		$ 0.01
Exercise price range, upper range limit | $ / shares																		$ 0.4
Number of options fully vested																							47,133
Number of options canceled																							31,500
Compensation expenses | $																							$ 21,798
Employees [Member] | Recent Option Grants 5 [Member]
Number of shares granted							339,000
Exercise price range, lower range limit | $ / shares							$ 0.2
Exercise price range, upper range limit | $ / shares							$ 0.4
Number of options fully vested																							139,000
Compensation expenses | $																							$ 40,747
Employees and Consultants [Member] | Recent Option Grants 2 [Member]
Number of shares granted																	1,466,700
Exercise price range, lower range limit | $ / shares																	$ 0.01
Exercise price range, upper range limit | $ / shares																	$ 0.4
Compensation expenses | $																							1,389,614
Consultants [Member] | Recent Option Grants 3 [Member]
Subscription price per share | $ / shares															$ 0.001
Number of shares granted															93,750
Compensation expenses | $																							$ 61,455
Executive, Director and Consultants [Member] | Recent Option Grants 4 [Member]
Number of shares granted								2,514,500
Exercise price range, lower range limit | $ / shares								$ 0.001
Exercise price range, upper range limit | $ / shares								$ 0.40
Number of options fully vested																							1,111,500
Number of options canceled																							450,000
Compensation expenses | $																							$ 396,222
Employee [Member]
Compensation expenses | $																						$ 76,616	$ 2,028,805

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Class E Warrant [Member] | Alimi Ahmed [Member]
Warrants	900,000
Warrant Term	0 years	[1]
Warrant Exercise Price | $ / shares	$ 0.0001
Warrant Exercisable	900,000
Investors [Member] | Class A Warrant [Member]
Warrants	6,334,626
Warrant Term	1 year
Warrant Exercisable	6,334,626
Investors [Member] | Class A Warrant [Member] | Minimum [Member]
Warrant Exercise Price | $ / shares	$ 0.14
Investors [Member] | Class A Warrant [Member] | Maximum [Member]
Warrant Exercise Price | $ / shares	$ 0.80
Investors [Member] | Class B Warrant [Member]
Warrants	5,400,478
Warrant Term	5 years
Warrant Exercise Price | $ / shares	$ 0.14
Warrant Exercisable	5,400,478
[1]	During 2015, a total of 2,700,000 Class E Warrants were issued by the Company to Lior Wayn pursuant to the terms of the Share Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the “Tranches”) at an exercise price of $0.0001 per Share, subject to and within 45 days of the Company achieving the milestones defined in the Share Exchange Agreement. On December 16, 2016, the Company terminated of Lior Way’s employment agreements with the Company and Emerald Israel., and his removal as an executive officer and director. During 2017, Mr. Wayn transferred, sold and assigned his 5,212,878 shares of the Company’s common stock and 900,000 Class E Warrants that were fully-vested to an entity controlled by Mr. Alimi Ahmed, then a member of the Company’s Board of Directors. Effective as of December 31, 2016, the remaining 1,800,000 Class E Warrants that had been issued to Mr. Wayn Warrants were canceled.

Stockholders' Equity - Summar32

Stockholders' Equity - Summary of Outstanding Warrants (Details) (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Mr. Wayn [Member]
Sale of stock, number of shares issued in transaction	5,212,878
Warrants issued, remaining		1,800,000
Class E Warrant [Member]
Issuance of warrants			2,700,000
Class E Warrant [Member] | Mr. Alimi Ahmed [Member]
Number of warrants vested	900,000
Class E Warrant [Member] | Tranche 1 [Member]
Issuance of warrants			900,000
Class E Warrant [Member] | Tranche 2 [Member]
Issuance of warrants			900,000
Class E Warrant [Member] | Tranche 3 [Member]
Issuance of warrants			900,000

Stockholders' Equity - Summar33

Stockholders' Equity - Summary of Employee Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Number of options, Outstanding at beginning of year	4,193,397	561,280
Number of options, Granted		5,440,483
Number of options, Exercised		(697,086)
Number of options, Cancelled	(4,130,397)	(550,000)
Number of options, Outstanding at end of year	62,500	4,193,397
Number of options, Options exercisable at end of period	62,500	3,288,062
Weighted average exercise price, Outstanding at beginning of year	$ 0.11	$ 0.0666
Weighted average exercise price, Granted		0.1336
Weighted average exercise price, Exercised
Weighted average exercise price, Cancelled	(0.11)	(0.3956)
Weighted average exercise price, Outstanding at end of year	0.01	0.11
Weighted average exercise price, Options exercisable at end of period	$ 0.01	$ 0.11
Aggregate intrinsic value, Outstanding at end of year		$ 1,006,415
Aggregate intrinsic value, Options exercisable at end of period		$ 789,134

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Options Outstanding Exercise Price Range (Details) - $ / shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Stock options outstanding		62,500	4,193,397
Weighted average remaining contractual life		8 years 2 months 30 days	9 years 2 months 30 days
Stock options exercisable		4,193,397	4,193,397
Exercise Price One [Member]
Exercise price		$ 0.4
Stock options outstanding			1,208,600
Weighted average remaining contractual life		0 years	9 years 2 months 30 days
Stock options exercisable			1,208,600
Exercise Price Two [Member]
Exercise price		$ 0.2
Stock options outstanding			1,870,000
Weighted average remaining contractual life		0 years	9 years
Stock options exercisable			1,870,000
Exercise Price Three [Member]
Exercise price	[1]
Stock options outstanding	[1]	62,500	1,114,797
Weighted average remaining contractual life	[1]	8 years 2 months 30 days	9 years 2 months 30 days
Stock options exercisable	[1]	62,500	1,114,797
[1]	0.01 or less

Stockholders' Equity - Schedu35

Stockholders' Equity - Schedule of Stock Options Outstanding Exercise Price Range (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stock option description	0.01 or less

Stockholders' Equity - Schedu36

Stockholders' Equity - Schedule of Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2017	[1]	Dec. 31, 2016
Equity [Abstract]
Expected volatility	0.00%		157.00%
Risk-free interest	0.00%		0.69%
Dividend yield	0.00%		0.00%
Expected life of up to (years)	0 years		6 years
[1]	There were no options granted during the year ended December 31, 2017.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Chairman [Member]
Outstanding to related party	$ 82,331	$ 125,896

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Total grants received			$ 222,000
Settlement amount to applicants		$ 96,000
Chief Executive Officer and Founder [Member]
Claim from damages	$ 100,000
Sales [Member]
Royalty rate percentage		3.50%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income tax reconciliation description	As a result of the tax act the maximum statutory federal tax rate was reduced to 21% starting on January 1, 2018.
Israeli [Member]
Net operating loss carry forwards		$ 3,193,927
Israeli [Member] | 2016 [Member]
Corporate tax rate	25.00%
Israeli [Member] | 2017 [Member]
Corporate tax rate	24.00%
Israeli [Member] | 2018 [Member]
Corporate tax rate	23.00%
U.S[Member]
Corporate tax rate	35.00%	35.00%
Net operating loss carry forwards		$ 15,150,925
Net operating losses expiration period		2,035

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net loss carry-forward	$ 18,344,852	$ 17,155,076
Total deferred tax assets	3,916,297	5,730,945
Valuation allowance	(3,916,297)	(5,730,945)
Net deferred tax assets

Restatement (Details Narrative)

Restatement (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Option Expire date		Jul. 15, 2018
Fair value of option
Fair value of derivative liabilities			$ 567
Alpha and Chi Squared [Member]
Options to purchase convertible notes and warrants	385,000
Alpha [Member]
Options to purchase convertible notes and warrants	350,000
Chi Squared Capital Inc [Member]
Options to purchase convertible notes and warrants	35,000
Fair value of option			336,272
Alpha Capital Anstalt [Member]
Fair value of option			$ 1,049,953

Restatement - Schedule of Resta

Restatement - Schedule of Restated Financial Statements (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Derivative liability		$ 336,272	[1]
Accumulated deficit	16,620,419	15,046,513	[1]
Total shareholders' deficit	(1,588,576)	(1,236,899)
Total finance income (expense)		(750,462)
Net Loss	$ (1,573,906)	(6,145,197)	[1]
As Reported [member]
Derivative liability
Accumulated deficit		14,670,241
Total shareholders' deficit		(900,627)
Total finance income (expense)		(414,190)
Net Loss		(5,808,925)
Adjustments [member]
Derivative liability		336,272
Accumulated deficit		336,272
Total shareholders' deficit		336,272
Total finance income (expense)		(336,272)
Net Loss		$ (336,272)
[1]	Restated - see Note 10.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 20, 2018	Mar. 19, 2018	Mar. 13, 2018	Mar. 12, 2018	Feb. 08, 2018	Jan. 26, 2018	Jan. 24, 2018	Jan. 23, 2018	Jan. 23, 2018	Nov. 10, 2016	Feb. 13, 2018	Dec. 31, 2017	Dec. 31, 2016	Jul. 31, 2016
Debt instrument principal amount												$ 920,484	$ 745,860	$ 100,000
Proceeds from issuance of common stock												536,613	$ 47,600
Stock issued during period, value, new issues
Guy Shalom [Member]
Number of warrant shares										119,000
Warrant exercise price										$ 0.80
Warrants exercisable										$ 119,000
Number of common stock shares issued										119,000
Stock issued during period, value, new issues										$ 47,600
Common Stock [Member]
Number of common stock shares issued												125,000
Stock issued during period, value, new issues												$ 12
Subsequent Event [Member]
Proceeds from issuance of convertible promissory notes								$ 100,000
Debt instrument interest rate								1.00%	1.00%
Conversion price per share								$ 0.01	$ 0.01
Number of restricted shares issued	1,092,500
Subsequent Event [Member] | Accredited Investors [Member]
Warrant exercise price											$ 0.14
Warrants exercisable term											24 months
Proceeds from issuance of common stock											$ 1,375,700
Number of common stock shares issued											19,647,856
Offering price per share											$ 0.07
Description on units offered											Unit consisting of: (i) one (1) share of common stock (the “Shares”); and (ii) one (1) common stock purchase warrant exercisable for a period of twenty-four (24) months to purchase one (1) additional Share at an exercise price of $0.14. (the “$0.07 Unit Offering”).
Number of restricted shares issued			3,928,571
Proceeds from subscription received			$ 277,100
Subsequent Event [Member] | Two Accredited Investors [Member]
Number of common stock shares issued					571,429
Stock issued during period, value, new issues					$ 80,000
Subsequent Event [Member] | Consultants [Member]
Number of restricted shares issued				2,600,000
Stock issued during period, value, issued for services				$ 676,000
Subsequent Event [Member] | Guy Shalom [Member]
Offering price per share	$ 0.01
Number of restricted shares issued	62,500
Subsequent Event [Member] | Common Stock [Member] | Accredited Investors [Member]
Number of common stock shares issued											1
Subsequent Event [Member] | Warrant [Member] | Accredited Investors [Member]
Number of common stock shares issued											1
Subsequent Event [Member] | Service Agreement [Member] | Yair Fudim [Member]
Offering price per share	$ 0.01
Number of restricted shares issued	300,000
Subsequent Event [Member] | Sellers [Member]
Debt instrument interest rate								1.00%	1.00%
Conversion price per share		$ 0.01					$ 0.01	$ 0.01	$ 0.01
Debt instrument principal amount							$ 956,209
Debt conversion, converted instrument, amount		$ 9,218					$ 73,000
Debt conversion, converted instrument, shares issued		921,800					7,300,000
Subsequent Event [Member] | Maz Partners [Member] | Consulting Agreement [Member] | Class H warrant [Member]
Number of warrant shares						200,000
Warrant exercise price						$ 0.14
Warrants exercisable						$ 1
Warrants exercisable term						2 years
Subsequent Event [Member] | Chiron Refineries Ltd. [Member]
Payment on appointment fee with VAT									$ 250,000
Payment for appointment fee									$ 150,000
Subsequent Event [Member] | Lyons Capital LLC [Member] | Engagement Letter [Member]
Number of restricted shares issued	730,000
Stock issued during period, value, issued for services	$ 124,100